Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis

The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval. Resultantly, the stock gains in pre-market trading.

Amgen (AMGN) Reports New Data From Lumakras Combo Study

Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.

4D Molecular (FDMT) to Start Studies on Cystic Fibrosis, Wet AMD

4D Molecular (FDMT) is set to initiate studies for gene-therapy candidates to treat cystic fibrosis lung disease and wet AMD, following FDA clearance of its two IND applications.

Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

Here's Why You Should Hold on to Illumina (ILMN) for Now

Investors are optimistic about Illumina (ILMN) owing to its strategic partnerships and wider market adoption of its products.

Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System

The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth

In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.

Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA

Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.

Regeneron's (REGN) sBLA for Libtayo Gets Priority Review

Regeneron's (REGN) application seeking the label expansion of PD-1 inhibitor Libtayo for the treatment of patients with recurrent or metastatic cervical cancer has been granted Priority Review.

Ekta Bagri headshot

4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace

New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.

Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

Here's Why You Should Retain QIAGEN (QGEN) Stock For Now

Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.

3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock

Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.

Is Horizon (HZNP) a Great Growth Stock?

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).

Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED

Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.

Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)

Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Techne (TECH) Soars to 52-Week High, Time to Cash Out?

Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.

AstraZeneca's (AZN) Rare Disease Study Meets Primary Goal

AstraZeneca's (AZN) phase III study evaluating ALXN1840 for Wilson disease achieves primary endpoint. The company also receives approval in Japan for Forxiga to treat chronic kidney disease.

Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal

Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.

Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study

Novartis' (NVS) phase III study evaluating Kymriah for second-line treatment of patients with aggressive B-cell NHL fails to achieve primary endpoint of the study.